← Back to patent-cliff list
Budesonide/Salmeterol xinafoate
Tier C — Watch / tradeBudesonide/Salmeterol xinafoate
Laboratoires Smb Sa
Originator
2015
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRB2, GR
Brand：Zephirus, Labazenit
Indications (approved)：Asthma
Regional status
US
-
EU
Approved
2015-01-01
China
-
Japan
-
Factories producing this API9
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
9 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates6 routes
Originator routes × 2Optimised (non-patent) × 4Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OriginatorRoute 1Steps 5 · Total yield /
Budesonide51333-22-3Budesonide-00137413-91-5Budesonide-00277017-20-0Budesonide-00391160-89-3Budesonide-00486401-80-1Budesonide-00513951-70-7Budesonide-006123-72-8API · Budesonide/Salmeterol xinafoate
| Code | CAS No. | Intermediate |
|---|---|---|
| Budesonide | 51333-22-3 | - |
| Budesonide-001 | 37413-91-5 | 2-((8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate |
| Budesonide-002 | 77017-20-0 | 2-((8S,10S,13S,14S,16R,17S)-16,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate |
| Budesonide-003 | 91160-89-3 | 2-((8S,9R,10S,11S,13S,14S,16R,17S)-9-bromo-11,16,17-trihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate |
| Budesonide-004 | 86401-80-1 | 2-oxo-2-((8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate |
| Budesonide-005 | 13951-70-7 | (8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one |
| Budesonide-006 | 123-72-8 | butyraldehyde |
OriginatorRoute 3Steps 8 · Total yield 100 g (Salmeterol xinafoate)
SALM-001629-03-8SALM-0023360-41-6SALM-00394749-73-2SALM-015163923-18-0SALM-01627475-14-5SALM-0171351281-52-1SALM-018943969-38-8SALM-01916475-90-4SALM-02027475-09-8API · Budesonide/Salmeterol xinafoate
| Code | CAS No. | Intermediate |
|---|---|---|
| SALM-001 | 629-03-8 | 1,6-dibromohexane |
| SALM-002 | 3360-41-6 | 4-phenylbutan-1-ol |
| SALM-003 | 94749-73-2 | (4-((6-bromohexyl)oxy)butyl)benzene |
| SALM-015 | 163923-18-0 | N-benzyl-6-(4-phenylbutoxy)hexan-1-amine hydrochloride |
| SALM-016 | 27475-14-5 | methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate |
| SALM-017 | 1351281-52-1 | methyl 5-(2-(benzyl(6-(4-phenylbutoxy)hexyl)amino)acetyl)-2-(benzyloxy)benzoate |
| SALM-018 | 943969-38-8 | 2-(benzyl(6-(4-phenylbutoxy)hexyl)amino)-1-(4-(benzyloxy)-3-(hydroxymethyl)phenyl)ethanol |
| SALM-019 | 16475-90-4 | methyl 5-acetyl-2-hydroxybenzoate |
| SALM-020 | 27475-09-8 | methyl 5-acetyl-2-(benzyloxy)benzoate |
OptimisedRoute 1Steps 8 · Total yield 0.24 g (Salmeterol)
SALM-001629-03-8SALM-0023360-41-6SALM-00394749-73-2SALM-00422483-09-6SALM-005736916-92-0SALM-006262856-97-3SALM-007262856-99-5SALM-00852113-69-6SALM-009262857-00-1SALM-010262857-01-2SALM-0112316-64-5API · Budesonide/Salmeterol xinafoate
| Code | CAS No. | Intermediate |
|---|---|---|
| SALM-001 | 629-03-8 | 1,6-dibromohexane |
| SALM-002 | 3360-41-6 | 4-phenylbutan-1-ol |
| SALM-003 | 94749-73-2 | (4-((6-bromohexyl)oxy)butyl)benzene |
| SALM-004 | 22483-09-6 | 2,2-dimethoxyethanamine |
| SALM-005 | 736916-92-0 | N-(2,2-dimethoxyethyl)-6-(4-phenylbutoxy)hexan-1-amine |
| SALM-006 | 262856-97-3 | benzyl (2,2-dimethoxyethyl)(6-(4-phenylbutoxy)hexyl)carbamate |
| SALM-007 | 262856-99-5 | benzyl (2-oxoethyl)(6-(4-phenylbutoxy)hexyl)carbamate |
| SALM-008 | 52113-69-6 | 6-bromo-2,2-dimethyl-4H-benzo[d][1,3]dioxine |
| SALM-009 | 262857-00-1 | benzyl (2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-hydroxyethyl)(6-(4-phenylbutoxy)hexyl)carbamate |
| SALM-010 | 262857-01-2 | 1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-((6-(4-phenylbutoxy)hexyl)amino)ethanol |
| SALM-011 | 2316-64-5 | 4-bromo-2-(hydroxymethyl)phenol |
OptimisedRoute 2Steps 2 · Total yield /
SALM-012115787-50-3SALM-01397664-55-6SALM-014163923-19-1API · Budesonide/Salmeterol xinafoate
| Code | CAS No. | Intermediate |
|---|---|---|
| SALM-012 | 115787-50-3 | 5-(2-bromoacetyl)-2-hydroxybenzaldehyde |
| SALM-013 | 97664-55-6 | N-benzyl-6-(4-phenylbutoxy)hexan-1-amine |
| SALM-014 | 163923-19-1 | 5-(2-(benzyl(6-(4-phenylbutoxy)hexyl)amino)acetyl)-2-hydroxybenzaldehyde |
OptimisedRoute 4Steps 5 · Total yield 204 g (Salmeterol xinafoate)
SALM-00394749-73-2SALM-0212084873-61-8SALM-0221690350-72-1SALM-0231995868-17-1SALM-024934842-69-0API · Budesonide/Salmeterol xinafoate
| Code | CAS No. | Intermediate |
|---|---|---|
| SALM-003 | 94749-73-2 | (4-((6-bromohexyl)oxy)butyl)benzene |
| SALM-021 | 2084873-61-8 | 2-acetoxy-5-(2-(benzylamino)acetyl)benzyl acetate |
| SALM-022 | 1690350-72-1 | 2-acetoxy-5-(2-(benzyl(6-(4-phenylbutoxy)hexyl)amino)acetyl)benzyl acetate |
| SALM-023 | 1995868-17-1 | 2-(benzyl(6-(4-phenylbutoxy)hexyl)amino)-1-(4-hydroxy-3-(hydroxymethyl)phenyl)ethanone |
| SALM-024 | 934842-69-0 | 4-(2-(benzyl(6-(4-phenylbutoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol |
OptimisedRoute 5Steps 11 · Total yield 1.3 g (Salmeterol xinafoate)
SALM-025119-36-8SALM-01916475-90-4SALM-02665033-21-8SALM-02765033-21-8SALM-01397664-55-6SALM-02871-43-2SALM-029108-30-5SALM-0302051-95-8SALM-0311821-12-1SALM-0322046-17-5SALM-0023360-41-6SALM-03313633-25-5SALM-034629-11-8API · Budesonide/Salmeterol xinafoate
| Code | CAS No. | Intermediate |
|---|---|---|
| SALM-025 | 119-36-8 | - |
| SALM-019 | 16475-90-4 | methyl 5-acetyl-2-hydroxybenzoate |
| SALM-026 | 65033-21-8 | - |
| SALM-027 | 65033-21-8 | - |
| SALM-013 | 97664-55-6 | N-benzyl-6-(4-phenylbutoxy)hexan-1-amine |
| SALM-028 | 71-43-2 | - |
| SALM-029 | 108-30-5 | - |
| SALM-030 | 2051-95-8 | - |
| SALM-031 | 1821-12-1 | - |
| SALM-032 | 2046-17-5 | - |
| SALM-002 | 3360-41-6 | 4-phenylbutan-1-ol |
| SALM-033 | 13633-25-5 | - |
| SALM-034 | 629-11-8 | - |
Frequently asked questions
What are the approved indications of Budesonide/Salmeterol xinafoate?
Approved indications include: Asthma.
When does the Budesonide/Salmeterol xinafoate patent expire?
No public expiry year is available for Budesonide/Salmeterol xinafoate yet; this page updates once verified.
How many synthesis routes are recorded for Budesonide/Salmeterol xinafoate?
6 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Budesonide/Salmeterol xinafoate intermediates?
All intermediates in Budesonide/Salmeterol xinafoate routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Budesonide/Salmeterol xinafoate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29